On this episode we had the pleasure of featuring Roy Maute of Pheast Therapeutics.
Pheast are unleashing the power of macrophages in oncology, starting in advanced solid tumours & Ovarian Cancer. Their pipeline consists of novel innate immune checkpoint inhibitors (incl. Anti-CD24), based on research out of Irv Weissman's lab at Stanford.
In this episode we cover the inspiration behind Roy's career in oncology R&D & the origins of Pheast's name & platform, before moving onto Pheast's recent (FTD, ph1 entry) and upcoming milestones. We also cover their big ambitions for the future & how their huge focus on culture as a business has & continues to shape their journey.
